Image Kyrapharm

Priority access to Orgapharm’s expertise and technologies

Custom synthesis with Orgapharm (Axyntis Group)

Due to its location on Orgapharm site, Kyrapharm benefits from the equipment and expertise of Orgapharm’s teams for developing organic synthesis projects, from the laboratory scale up to the industrial scale:

  • R&D and analytical laboratories and an experienced, flexible team, close to the production teams
  • A cGMP pilot plant enabling intermediate scale-up to be studied and the manufacturing of batches for pre-clinical to commercial phases
  • cGMP production units:
    • Multipurpose equipment: reactors ranging from 20 L to 6,300 L, glasslined and stainless steel, with a total reactor capacity of 90 m3, offering a wide range of technologies: cryogenic conditions (down to -80° C), hydrogenation, halogenation, cyanation, asymmetric synthesis, high temperature conditions(up to 250° C), batch or thin layer distillation, crystallisation unit, etc.
    • A finishing workshop enabling isolation and finishing/packaging of the main active ingredients in a controlled atmosphere.
    • A large range of analysis equipment: HPLC and gas chromatography, UV and IR spectroscopy, DSC, titration, etc.
    • Stability chambers to test ICH stability.
Orgapharm synthesis plant

The Axyntis Group, an intermediate-sized company with estimated turnover of €100 M in 2014 and more than 420 employees, is a leading speciality chemicals company in France thanks to its GMP capabilities (700 m3). The group owns six sites (All’Chem in Montluçon, Centipharm in Grasse, Orgapharm in Pithiviers, Steiner in Saint Marcel and Synthexim in Calais, withtwo sites) and three R&D centres, all located in France. Its activities revolve around the life sciences (pharmacy, animal health, agrochemicals), dyes and speciality fine chemicals (electronics, photography, cosmetics, flavourings and perfumes, etc.)
www.axyntis.com

Orgapharm, located in Pithiviers, is a subsidiary of the Axyntis Group. The site employs 95 people and has a total reactor volume of 90 m3. It has been inspected by the Food and Drug Administration (last inspection in 2014), the French National Agency for Drug and Health Product Safety (ANSM) and is also ISO 14001 certified. Main Axyntis Research & Development centre is located at Orgapharm, together with a GMP pilot plant as well as multipurpose synthesis plants and an automated GMP crystallisation/finishing unit. The entire production cycle is covered, from the laboratory to industrial production, thereby enabling support for a project in its entirety.